SEC Form 4 · accession 0001209191-15-058117

AMICUS THERAPEUTICS, INC. · FOLD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP, Chief Patient Advocate

Period of report

Jul 1, 2015

Accepted (ET)

Jul 1, 2015 · 5:27 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001178879

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common stock^F2	Jul 1, 2015	M	10,649	$13.9748	A	16,342	D
Common stock^F3	Jul 1, 2015	S	10,649	$13.9748	D	5,693	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Options (right to buy)	$3.53	Jul 1, 2015	M	4,374	D	Jan 28, 2014	Jan 28, 2023	Common Stock	4,374	26,252	D
Stock Options (right to buy)	$2.52	Jul 1, 2015	M	3,463	D	Jun 18, 2014	Jun 18, 2023	Common stock	3,463	28,075	D
Stock Options (right to buy)	$2.45	Jul 1, 2015	M	2,812	D	Jan 3, 2015	Jan 3, 2024	Common stock	2,812	39,376	D

F1The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
F2This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.87 to $14.15. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F3This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.87 to $14.15. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.